Resources

Discover how partnering with TriNetX will enable you to advance rare disease research.

In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.

Pediatric obstructive sleep apnea (OSA) affects an estimated 1–3 % of children, corresponding to over 40 million cases globally.

Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.

Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting

Dr. David Karp, Chief of the Division of Rheumatic Diseases at UT Southwestern Medical Center, leads research efforts in systemic lupus erythematosus (SLE), a rare and complex autoimmune condition that disproportionately affects women of color.

Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum.

Clinical trials often falter at the final stretch—when it’s time to execute. It’s here that well-intentioned protocols meet real-world complexity, where timelines can slip, costs may surge, and outcomes could fall short of expectations.

This TriNetX exclusive survey report reveals how 150 senior pharmaceutical and biotech executives are leveraging artificial intelligence, real-world data (RWD), and diversity in clinical trials to drive innovation—while navigating persistent challenges.

In the high-stakes world of clinical research, innovation doesn’t just happen in the lab; it must cross the clinical trial finish line of regulatory submission. Yet for many sponsors, sites, and researchers, patient recruitment—or the “last mile”—remains a costly bottleneck where recruitment can lag, site enrollment can underperform, and promising treatments never receive approval.

The “last mile” of clinical research represents the crucial phase where protocols are put into action, and patient engagement becomes a reality. It’s about transforming well-laid plans into meaningful outcomes by efficiently connecting researchers, sites, and participants.

The path to groundbreaking discoveries in clinical research starts with a single, vital element: trusted data.